8-K - Sunshine Biopharma, Inc (0001402328) (Filer)
10-Q/A - Sunshine Biopharma, Inc (0001402328) (Filer)
8-K - Sunshine Biopharma, Inc (0001402328) (Filer)
4 - Sunshine Biopharma, Inc (0001402328) (Issuer)
4 - Sunshine Biopharma, Inc (0001402328) (Issuer)
3 - Sunshine Biopharma, Inc (0001402328) (Issuer)
On June 28, 2024, Sunshine Biopharma, Inc. (the "Company") received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq"), informing the Company that the Nasdaq Hearings Panel has granted the Company's request for an exception until August 26, 2024, to regain compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2)
Gainers Geovax Labs (NASDAQ:GOVX) stock moved upwards by 72.1% to $1.91 during Wednesday's regular session. The company's market cap stands at $4.8 million. Nexalin Technology (NASDAQ:NXL) shares increased by 43.06% to $1.08. The market value of their outstanding shares is at $8.0 million. Vaxart (NASDAQ:VXRT) shares rose 33.45% to $0.7. The market value of their outstanding shares is at $123.8 million. Sunshine Biopharma (NASDAQ:SBFM) stock increased by 28.92% to $0.39. The market value of their outstanding shares is at $7.4 million. Portage Biotech (NASDAQ:PRTG) shares increased by 25.0% to $0.3. The company's market cap stands at $5.9 million. Silk Road Medical (NASDAQ:SILK) shares
Gainers Nexalin Technology (NASDAQ:NXL) shares rose 55.8% to $1.62 during Tuesday's after-market session. The market value of their outstanding shares is at $12.0 million. Dynatronics (NASDAQ:DYNT) stock rose 14.74% to $0.4. The company's market cap stands at $2.1 million. Oncology Institute (NASDAQ:TOI) shares moved upwards by 10.8% to $0.45. The market value of their outstanding shares is at $33.5 million. SAB Biotherapeutics (NASDAQ:SABS) stock rose 8.94% to $2.8. The market value of their outstanding shares is at $25.8 million. Bone Biologics (NASDAQ:BBLG) shares moved upwards by 8.04% to $1.61. The company's market cap stands at $1.7 million. Virpax Pharmaceuticals (NASDAQ:VRPX) s
SC 13G - Sunshine Biopharma, Inc (0001402328) (Subject)
SC 13G - Sunshine Biopharma, Inc (0001402328) (Subject)
SC 13G - Sunshine Biopharma, Inc (0001402328) (Subject)
4 - Sunshine Biopharma, Inc (0001402328) (Issuer)
4 - Sunshine Biopharma, Inc (0001402328) (Issuer)
MONTREAL, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately. As such, Nora Pharma Inc. is now a wholly owned subsidiary of Sunshine Biopharma Inc. Nora Pharma is one of North America's fastest growing generic pharmaceuticals companies. The addition of Nora Pharma allows Sunshine Biopharma to expand its operations into the area of generic prescription drugs and biosimilars. The purchase price of $30,000,000 Canadian (approxi
Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18%Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both submicromolar potency and animal model efficacyXR8-23 (Compound 10) showed significant drug accumulation in lung of mice and favorable pharmacokinetic propertiesResearch was conducted in collaboration with the University of Arizona FORT LAUDERDALE, FL / ACCESSWIRE / September 4, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the
FORT LAUDERDALE, FL / ACCESSWIRE / August 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has launched nine (9) new generic prescription drugs year-to-date. These launches bring the total number of drugs that the Company has on the market in Canada to sixty-one (61). The Company's marketing and sales efforts are carried out by Nora Pharma Inc. (Nora Pharma), a wholly owned subsidiary of the Company.The new generic prescription drugs launched include Abiraterone, Clobetasol, Daptomycin, Dasatinib, Ertapenem, Hanz
FORT LAUDERDALE, FL / ACCESSWIRE / August 19, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2024 second quarter report with the Securities and Exchange Commission. The Company reported gross revenues of $9,303,067 for the three months ended June 30, 2024, a 67% increase over gross revenues of $5,560,865 for same period in 2023. For the six-month period ended June 30, 2024, gross revenues were $16,844,113, compared to gross revenue of $10,454,918 for the same period in 2023, an increase of 61%. These